Evidence map›Paper›PMID 22118419›Full record

ArticleRadiation oncology (London, England)2011

Significant impact of different oxygen breathing conditions on noninvasive in vivo tumor-hypoxia imaging using [¹⁸F]-fluoro-azomycinarabino-furanoside ([¹⁸F]FAZA).

Florian C Maier, Manfred Kneilling, Gerald Reischl, Funda Cay, Daniel Bukala, Andreas Schmid, Martin S Judenhofer, Martin Röcken, Hans-Jürgen Machulla, Bernd J Pichler

Open access · goldAbstract read
In one paragraph

Article in Radiation oncology (London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Fluorinated carbohydrates forChemical Society reviews · 2023
    Review
  2. Kinetic Evaluation of the Hypoxia Radiotracers [Nuclear medicine and molecular imaging · 2023
    Article
  3. Article
  4. Review
  5. Article
  6. Molecular imaging of hypoxia in non-small-cell lung cancer.European journal of nuclear medicine and molecular imaging · 2015
    Review
  7. Article
  8. Review
  9. Article
  10. A comparison of the imaging characteristics and microregional distribution of 4 hypoxia PET tracers.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2014
    Article
  11. PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence.American journal of nuclear medicine and molecular imaging · 2014
    Review
  12. Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patients.European journal of nuclear medicine and molecular imaging · 2013
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Florian C MaierDepartment of Preclinical Imaging and Radiopharmacy, Laboratory for Preclinical Imaging and Imaging Technology of the Werner Siemens-Foundation, University of Tübingen, Germany.
Manfred Kneilling
Gerald Reischl
Funda Cay
Daniel Bukala
Andreas Schmid
Martin S Judenhofer
Martin Röcken
Hans-Jürgen Machulla
Bernd J Pichler
University of Tübingen · DESiemens (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background[18F]FAZA is a PET biomarker with great potential for imaging tumor hypoxia. Aim of our study was to compare [18F]FAZA uptake in mice with subcutaneous exogenous CT26 colon carcinomas and endogenous polyoma middle-T (PyV-mT) mammary carcinomas and to analyze the influence of different breathing protocols in CT26 colon carcinomas as well as the reversibility or irreversibility of [18F]FAZA uptake.

methodsWe injected subcutaneous CT26 colon carcinoma or polyomavirus middle-T (PyV-mT) mammary carcinoma-bearing mice intravenously with18F-FAZA and performed PET scans 1-3 h post injection (p.i.). To analyze the impact of oxygen supply in CT26 carcinomas we used three different breathing protocols: (P0) air; (P1) 100% oxygen 1 h prior injection until 3 h p.i.; (P2) 100% oxygen breathing starting 2 min prior tracer injection until 1 h p.i. and during the PET scans; mice were breathing air between the 2 h and 3 h 10 min static scans. Normalized PET images were analyzed by using defined regions of interest. Finally, some mice were dissected for pimonidazole immunohistochemistry.

resultsThere was no difference in18F-FAZA uptake 1-3 h p.i. between the two carcinoma types (CT26: 1.58 ± 0.45%ID/cc; PyV-mT: 1.47 ± 0.89%ID/cc, 1 h p.i., tumor size < 0.5 cm3). We measured a significant tracer clearance, which was more pronounced in muscle tissue (P0). The [18F]FAZA tumor-to-muscle-ratios in CT26 colon carcinoma-bearing mice 2 h and 3 h, but not 1 h p.i. were significantly higher when the mice breathed air (P0: 3.56 ± 0.55, 3 h) compared to the oxygen breathing protocols (P1: 2.45 ± 0.58; P2: 2.77 ± 0.42, 3 h). Surprisingly, the breathing protocols P1 and P2 showed no significant differences in T/M ratios, thus indicating that the crucial [18F]FAZA uptake phase is during the first hour after [18F]FAZA injection. Importantly, the muscle clearance was not affected by the different oxygen breathing conditions while the tumor clearance was lower when mice were breathing air.

conclusionExogenous CT26 colon carcinomas and endogenous polyoma middle-T (PyV-mT) mammary carcinomas showed no differences in [18F]FAZA uptake 1-3 h p.i. Our analysis using various breathing protocols with air (P0) and with pure oxygen (P1, P2) clearly indicate that [18F]FAZA is an appropriate PET biomarker for in vivo analysis of hypoxia revealing an enhanced tracer uptake in tumors with reduced oxygen supply. [18F]FAZA uptake was independent of tumor-type.

Indexed as

NitroimidazolesRadiopharmaceuticalsRespirationAnimalsCell HypoxiaDiagnostic ImagingFluorine RadioisotopesHypoxiaImage Processing, Computer-AssistedImmunohistochemistryMiceMice, Inbred BALB CMice, Inbred C57BLNeoplasms, ExperimentalOxygenPositron-Emission TomographyFluorine Radioisotopesfluoroazomycin arabinosideNitroimidazolesOxygenRadiopharmaceuticalsRibose

Identifiers

PMID22118419
PMCPMC3283532
OpenAlexW2137029201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.